This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Headquartered in Woonsocket, RI, CVS Health Corporation (formerly known as CVS Caremark Corporation) is a pharmacy innovation company with integrated offerings across the entire spectrum of pharmacy care. On Sep 3, 2014, CVS Caremark Corporation announced a change of its corporate name to CVS Health to reflect its broader health care commitment. In Nov 2018, CVS Health completed the $70-billion consolidation of insurance-giant Aetna. With the acquisition, the segments of CVS Health have been realigned.
CVS Health (CVS) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
CVS Health (CVS) closed the most recent trading day at $84.23, moving -0.6% from the previous trading session.
Top Stock Reports for Apple, Home Depot & Sanofi
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Apple (AAPL), The Home Depot (HD), and Sanofi (SNY).
Amazon's Physical Pharmacy Not a Grave Threat: 3 Stocks to Buy
by Urmimala Biswas
Investors should not lose optimism and continue to discover the enormous business opportunities this retail pharmacy- drug store industry holds. Here are three stocks, WMT, UNH, HLF, which you can grab now.
CVS Health (CVS) Introduces Changes in ExtraBucks Program
by Zacks Equity Research
CVS Health's (CVS) retail division to offer instant 2% ExtraBucks rewards on purchases through the ExtraCare Rewards loyalty program.
CVS Health (CVS) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
CVS Health (CVS) closed at $84.74 in the latest trading session, marking a -0.77% move from the prior day.
3 Stocks With Telehealth Offerings for Post-Pandemic Gains
by Riya Anand
Stocks like CVS Health (CVS), Walgreens Boots Alliance (WBA) and Allscripts (MDRX) are expected to continue to grow post-pandemic on a series of remote health care product and service launches.
CVS Health (CVS) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
CVS Health (CVS) closed at $85.50 in the latest trading session, marking a +0.65% move from the prior day.
Federal Realty (FRT) Boosts Portfolio With Buyouts, Stock Up
by Zacks Equity Research
Federal Realty's (FRT) recent acquisitions offer scope for value creation through redevelopment, merchandising and capital investment.
CVS Health (CVS) Deploys Time-Delay Safes in Georgia Pharmacies
by Zacks Equity Research
CVS Health's (CVS) time-delay safes are anticipated to help reduce robbery incidents.
Here's Why You Should Retain CVS Health (CVS) in Your Portfolio
by Zacks Equity Research
Investors are optimistic about CVS Health (CVS) on solid first-quarter performance and growth in digital health services.
Splunk (SPLK) Q1 Earnings Miss Estimates, Revenues Up Y/Y
by Zacks Equity Research
Splunk's (SPLK) first-quarter fiscal 2022 results reflect growth in cloud revenues and customer base expansion despite decline in license revenues.
Why Is CVS Health (CVS) Up 3.6% Since Last Earnings Report?
by Zacks Equity Research
CVS Health (CVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Cigna (CI) Rides on Acquisitions, Strong Capital Deployment
by Zacks Equity Research
Cigna (CI) looks well poised for growth on the back of its acquisitions, membership strength and other growth strategies.
CVS Health (CVS) Launches Clinical Trial Services Business
by Zacks Equity Research
The latest clinical trial experience from CVS Health (CVS) is expected to overcome multiple challenges posed by its current clinical trial model.
CVS Health (CVS) Gains From Digitalization, Hurt by Seasonality
by Zacks Equity Research
CVS Health's (CVS) consumer-centric digital strategy is now more relevant in the current environment as people are using technology while staying indoors.
Top Analyst Reports for Cisco, Sanofi & Charles Schwab
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Cisco Systems, Inc. (CSCO), Sanofi (SNY), and The Charles Schwab Corporation (SCHW).
The Zacks Analyst Blog Highlights: Nike, CVS Health, American Tower Corp, The Southern Co, American International Group and Parker-Hannifin Corp
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Nike, CVS Health, American Tower Corp, The Southern Co, American International Group and Parker-Hannifin Corp
Top Stock Reports for Nike, CVS Health & American Tower
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including NIKE, Inc. (NKE), CVS Health Corporation (CVS), and American Tower Corporation (AMT).
CVS Health (CVS) Gains As Market Dips: What You Should Know
by Zacks Equity Research
CVS Health (CVS) closed the most recent trading day at $81.12, moving +4.41% from the previous trading session.
CVS Health (CVS) Q1 Earnings Beat Estimates, EPS View Up
by Zacks Equity Research
CVS Health's (CVS) revenues across all the three operating segments improve in Q1. Increased guidance amid the pandemic scenario is another positive.
CVS Health (CVS) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
CVS Health (CVS) delivered earnings and revenue surprises of 18.60% and 0.96%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Gears for a Hectic Earnings Week
by Zacks Equity Research
Wall Street Gears for a Hectic Earnings Week.
Will Central Banks Start to Care About Fundamentals?
by John Blank
Macro-data has been much stronger than expected.¿¿¿¿¿¿ Still, the only thing that matters is NOT whether stock traders (or pundits) take note of strong data. It is whether the Fed and other major central banks care.
Markets Up to Start Another Busy Week
by Mark Vickery
With Q1 earnings season continuing to unfold favorably (for the most part), investors look to enjoy a healthy Q2, as well.
Is a Beat in the Cards for CVS Health (CVS) in Q1 Earnings?
by Zacks Equity Research
Given the increasing number of walk-in-clinical appointments and patient visits, CVS Health (CVS), which has a huge PBM client base, is expected to have seen a sequential rebound in Q1 revenues.